ritanserin

Ritanserin is a potent and selective serotonin (5-hydroxytryptamine, 5-HT) receptor antagonist, primarily targeting the 5-HT2A and 5-HT2C subtypes with high affinity. It also exhibits antagonistic activity at other serotonin receptors including 5-HT1D, 5-HT2B, 5-HT5A, 5-HT6, and 5-HT7 but has much lower affinity for histaminergic (H1), dopaminergic (D2), and adrenergic (α1 and α2) receptors. Developed originally by Janssen as an investigational drug for psychiatric disorders such as anxiety, depression, schizophrenia, and cocaine-related disorders, ritanserin was never approved or marketed for clinical use. Its mechanism of action involves blocking the effects of serotonin at the targeted receptors in the central nervous system. Ritanserin is classified chemically as a piperidine-pyrimidinone derivative[1][3][4][5].

Other names

ritanserina